Clinical trial NCT04191616 - References

Relapsed or Refractory Multiple Myeloma — Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Citation(s)

•   Perrot A, Delimpasi S, Spanoudakis E, Frolund U, Belotti A, Oriol A, Moreau P, McFadden I, Xia Q, Arora M, Dimopoulos MA
  An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leuk Lymphoma. 2024 Mar 18:1-10. doi: 10.1080/10428194.2024.2322030. Online ahead of print.

An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma With Carfilzomib, Pomalidomide, and Dexamethasone (KPd)

Details for clinical trial NCT04191616